Moreover, The detection of PTCH1 mutations may provide a more accessible way to stratify MSI-H/dMMR CRC patients for immunotherapy, though a study using a larger cohort would be necessarty to validate these findings. The gene discussed is PTCH1; the disease is colorectal carcinoma.